| 2025 | 2024 | |||
|---|---|---|---|---|
| Gross margin | 36,8 k € | +6.3% | 34,6 k € | |
| EBITDA | 36,6 k € | +7.0% | 34,3 k € | |
| Operating profit | 36,6 k € | +7.0% | 34,3 k € | |
| Profit/loss | 22,4 k € | +60.3% | 13,9 k € | |
| Equity | 46,3 k € | +93.3% | 23,9 k € | |
| Total assets | 269,7 k € | +3.1% | 261,6 k € | |
| Cash | 5,2 k € | -41.7% | 8,8 k € | |
| Debts | 221,9 k € | -6.0% | 236,2 k € | |
Source: Belgian Official Gazette
Private limited company · Geel · incorporated on 10/03/2023
Private limited company profitable and well capitalised. Cash position declining (-41.7%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
Helsen Pharma & Consulting is a Private limited company incorporated in 2023. Its main activity is: Fund management activities. Its registered office is in Geel.